OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

OncoSec execs may be regretting their decision to release preliminary Phase IIb data on the combination of Merck’s Keytruda and their big pipeline play Tavo.